AHF: EU Should Ditch Patents During Health Crises
“We applaud the EU for taking action before another health emergency strikes.
- “We applaud the EU for taking action before another health emergency strikes.
- Getting bogged down in patent disputes during a pandemic leads to lives lost—that’s completely unacceptable regardless of how much big pharma objects,” said AHF Europe Bureau Chief Zoya Shabarova.
- “However, EU actions should not be limited to compulsory licensing.
- IP rights waivers should become an integral part of a health crisis management toolbox embedded in pharmaceutical legislation, TRIPS revisions, and the upcoming Pandemic Accord.”